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Prognostic implication of serum cytokeratin 19 fragments (CYFRA 21-1) was explored in 60 advanced NSCLC patients, whereas in
45 patients assessable for serological response a X35% CYFRA 21-1 decline after two chemotherapy cycles was strongly associated
with non-progression (NP), defined as a sum of objective response (OR)þstable disease (Po0.0001) and survival (P¼0.0002).
Association of OR with survival was not significant. In multivariate survival analysis, X35% marker decline and radiological NP status
were found as major determinants of prolonged survival with RR: 0.37 (P¼0.01) and 0.63 (P¼0.01), respectively. In advanced
NSCLC patients, NP reflects therapeutic efficacy better than traditional OR. CYFRA 21-1 X35% decline seems to be a reliable
surrogate marker of treatment efficacy in terms of survival.
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Combination chemotherapy for advanced non-small-cell lung
cancer (NSCLC) is clinically beneficial in only about half of the
treated naive patients, and most responses are partial.
The decision whether to continue or to stop therapy is
traditionally guided by imaging-based tumour response evalua-
tion, which is regarded a surrogate marker of clinical benefit.
Assessment by structural imaging has known limitations and also
may have a poor correlation with pathologic response in NSCLC
(Martini et al, 1988).
Furthermore, it has been shown that objective response
(OR) is not a wholly reliable prognosticator of survival (Gandara
et al, 1999). In this context, the diagnostic and prognostic potential
of biochemical markers, such as circulating cytokeratin 19
fragments (CYFRA 21-1), in monitoring antineoplastic therapy
has been investigated (Ebert and Muley 1999, Ardizzoni et al,
2006).
In the present study, we compared CYFRA 21-1 change with
clinical response after two chemotherapy cycles in order to find
out which one correlates better with patients’ survival.
PATIENTS AND METHODS
Patients
This prospective, IRB approved, study included 60 chemo-
therapy-naive patients enrolled between 1 January 1998 and
1 July 2003. Patient characteristics are presented in Table 1. The
median age was 61 years (37–77 years). All patients received a
minimum of two, and up to eight (median 5) chemotherapy cycles
(¼courses). Specific regimens are presented in Table 1. CT scans
were performed every two cycles. All patients had measurable
disease. A functional state was graded by the Eastern Cooperative
Oncology Group (ECOG) performance status (PS) scale.
Two response categories were explored: OR (complete response
(CR)þpartial response (PR)) and non-progression – NP
(CRþPRþstable disease (SD)). Patients achieving either OR or
NP were classified as responders, whereas those with no response
(NR) (SDþprogressive disease (PD)) or PD, respectively, were
considered non-responders.
Methods
Serum samples were obtained before the start and after the second
chemotherapy course at the time of clinical response evaluation
and stored at  801C until analysis. Cytokeratin 19 fragments were
measured by immunoradiometric ELSA-CYFRA 21-1 kit (CIS Bio
International, Gif-sur Yvette, France). The cut-off value was
3.2ngml
 1. It provided 95% specificity in the group of patients
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swith benign lung diseases (Nisman et al, 1998). From two serum
samples, pretreatment and that obtained after two cycles of
chemotherapy, at least one was required to be above the normal
cut-off (3.2ngml
 1) to have the CYFRA 21-1 change assessable
disease.
Statistical analysis
Non-parametric tests were used for comparisons between numeric
variables, the Wilcoxon signed-rank test for CYFRA 21-1 before
and after treatment and Mann–Whitney for independent groups.
Spearman’s correlations were reported. Associations between
categorical variables were evaluated with the w
2-test. The Youden
index was used to identify the optimal decline in CYFRA 21-1 for
the diagnosis of NP or OR (Armitage, 1971). Univariate analyses of
the prognostic impact of various factors on survival from response
evaluation (i.e., landmark time of 6 weeks) to death or last
follow-up used the Kaplan–Meier method and log-rank test.
Variables statistically significant (Po0.05) in the univariate steps
were entered into multivariate Cox regression models (Cox, 1972).
The proportional hazard assumption was examined in log minus
log plots and found acceptable. A value of Po0.05 was considered
significant.
RESULTS
Whole study population (N¼60)
Pre- and post-treatment, two-course median CYFRA 21-1 were
5.5ngml
 1 (range 0.89–88.6ngml
 1) and 2.2ngml
 1 (range
0.28–64.1ngml
 1), respectively. Between two consecutive measure-
ments, CYFRA 21-1 showed a significant decline (P¼0.001).
Median marker change in OR ( 76%) was close to that of SD
( 58%) (P¼0.7), but significantly higher than that in PD (5%)
(P¼0.003).
In OR and NR subgroups, the median CYFRA 21-1 changes after
two courses did not differ significantly ( 76 and  34%,
respectively, P¼0.1); whereas in NP, the median change was
significantly larger than in PD ( 68 and 5%, respectively,
P¼0.001).
CYFRA 21-1 levels were above the cut-off limit (3.2ngml
 1)i n
43 (71.7%) and in 24 (40%) of 60 patients pre- and post-treatment
two courses, respectively. In only 2 out of 60 patients (3.3%),
elevation greater than cut-off level occurred during initial therapy.
Overall median survival from the landmark time was 12.7
months. Median survival of either OR and or SD patients was
significantly longer than that of PD patients (16.3 and 14 vs 6.1
months; Po0.0001 and P¼0.0005, respectively), whereas OR and
SD patients were similar (P¼0.69). Non-progression patient’s
median survival was 15.1 months.
Table 2 depicts patient characteristics, biochemical parameters
and the response category, associated with survival. Association
of OR with survival did not reach statistical significance (P¼0.06).
When pretreatment significant parameters were included in the
Cox model, an independent prognostic status was retained for
PS (relative risk (RR): 2.0; 95% CI 1.1–3.5; P¼0.03), stage
(RR: 1.9; 95% CI 1.1–3.4; P¼0.02) and pre-treatment CYFRA 21-1
(1-CYFRA 21-1) (RR: 0.5; 95% CI 0.3–0.9; P¼0.02). When,
however, the aforementioned three variables were complemented
by post-treatment two courses CYFRA 21-1 (2-CYFRA 21-1) and
NP, only the latter two stayed independent with a RR: 0.40; 95% CI
0.19–0.84; P¼0.01 and RR: 0.55; 95% CI 0.39–0.76, Po0.001,
respectively.
Subgroup of patients with CYFRA 21-1 change assessable
disease (N¼45)
According to the used criterion presented in the method section,
45 patients were found to have disease assessable for marker
Table 1 Patient and disease characteristics
Characteristics n
Gender
Males/Females 43/17
Age (years)
p61/461 32/28
Stage
IIIA/IIIB/IV 5/18/37
ECOG PS
0–1/2 41/19
Tumour histology
Adenocarcinoma 29
Squamous 9
Large cell 17
Unclassified NSCLC 5
First line chemotherapy
Cisplatin+gemcitabine 29
Carboplatin+paclitaxel 23
Carboplatin+etoposide 6
Others 2
Clinical response
CR/PR/SD/PD 1/16/22/21
Status at last follow-up
Alive/dead of tumour 1/59
ECOG PS¼Eastern Cooperative Oncology Group performance status;
NSCLC¼non-small-cell lung cancer; CR¼complete response; PR¼partial re-
sponse; SD¼stable disease; PD¼progressive disease.
Table 2 Univariate survival analyses in 60 patients with NSCLC (only
variables with Po0.1 were included)
Characteristics N MS (months) 95% CI P-value log rank
Stage
IIIA-IIIB 23 13.7 11.7–15.7 0.04
IV 37 8.9 3.9–13.9
ECOG PS
p1 41 13.0 10.9–15.1 0.02
41 19 7.5 1.4–13.6
NP
Yes 39 15.1 13.0–17.2 o0.0001
No 21 6.1 2.7–9.5
OR
Yes 17 16.3 11.0–21.6 0.06
No 43 8.8 3.9–13.6
1-CYFRA 21-1 (ngml
 1)
p3.2 17 19.5 11.4–27.6 0.01
43.2 43 10.6 5.8–15.4
2-CYFRA 21-1 (ngml
 1)
p3.2 36 15.1 13.5–16.7 o0.0001
43.2 24 6.2 5.2–7.2
1-CYFRA 21-1¼pretreatment CYFRA 21-1; 2-CYFRA 21-1¼CYFRA 21-1 after
two cycles of chemotherapy; CI¼confidence interval; ECOG PS¼Eastern
Cooperative Oncology Group performance status; MS¼median survival time;
NSCLC¼non-small-cell lung cancer; NP¼non-progression; OR¼objective response.
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sresponse. In this subgroup, the CYFRA 21-1 declines, best
correlating with NP and OR corresponded to a X35 and X62%
reduction in CYFRA 21-1 after two chemotherapy courses (marker
response-35 and marker response-62, respectively).
The cut-off X35% was 84.6% sensitive and 79% specific in the
diagnosis of NP (accuracy, 82.2%). Marker response-35 was
achieved in 22 out of 26 NP patients but only in 4 out of 19 PD
patients (Po0.0001). Response-35 conferred a longer survival
(14.0 months vs 6.1 months, P¼0.0002).
Marker response-62 was 90% sensitive and 60% specific with
regard to OR (accuracy, 66.7%). It occurred in 9 out of 10 OR and
in 14 out of 35 NR patients (P¼0.02). Patients who had X62%
CYFRA 21-1 reduction survived 14 vs 6.6 months for those who
had a lesser decrease (P¼0.02).
Non-progression patients showed a far better survival as
compared to PD patients (14.0 vs 6.1 months, Po0.0001). Survival
difference between OR and NR patients was not significant (P¼0.3).
When PS, marker response-35 and NP were included in the Cox
model, only marker response-35 (RR: 0.4; 95% CI 0.2–0.8;
P¼0.01) and NP (RR: 0.6; 95% CI 0.4–0.9; P¼0.01), but not PS
(RR: 1.8; 95% CI 0.9–3.5; P¼0.11), remained significant
determinants of survival.
We investigated the prognostic role of CEA changes during
chemotherapy as well. In the univariate analysis, CEA response
(X35% decline) was found to be associated with prolonged
survival (14.0 vs 8.8 months; P¼0.04). Being included in the Cox
model with PS and NP, CEA response, however, did not retain
significance (P¼0.78).
DISCUSSION
This is the first study comparing the prognostic impact of two
clinical response category groups, namely OR and NP, with two
corresponding CYFRA 21-1 responses differing in magnitude of
decline.
Our study together with a previous report (Lara et al, 2006)
questions the validity of OR as a survival indicator. It shows the
survival of SD standing more close to OR than to PD patient
categories, suggesting that a stable disease by NSCLC chemo-
therapy contributes significantly to patients’ survival. Thus, NP
(PRþSD) appears to measure treatment efficacy more accurately
than traditional OR.
In the study, we found that chemotherapy-induced CYFRA 21-1
changes had a strong association with both radiological response
(OR, SD and PD) and survival. Furthermore, the CYFRA 21-1
change at SD were closer to that in OR than in PD, corroborating
Ebert and Muley (1999) study of inoperable NSCLC patients.
In addition to known unfavourable prognostic implication of
high pretreatment CYFRA 21-1 in advanced NSCLC (Pujol et al,
2004), we have observed that therapy-induced 2-CYFRA 21-1
impacts survival even more. Inclusion of 2-CYFRA 21-1 and NP in
the Cox model replaced pretreatment CYFRA 21-1, PS and stage of
disease, becoming the major determinants of survival with relative
risks 0.40 and 0.55, respectively.
In the subgroup of 45 patients with serologically assessable
disease, the marker declines best associated with clinical OR and
NP outcomes comprised 62 and 35%, respectively.
Clinically, NP is more meaningful than OR; interestingly,
marker response-35 reflected NP and survival better than marker
response-62 for OR and survival. We suggest that NP, incorporating
SD, really groups the patients benefiting from therapy. These two
parameters have an independent impact as prognostic factors for
survival.
High accuracy of the marker response-35 in diagnosis of NP and
its strong association with survival makes it possible to use it as a
reliable surrogate marker of treatment efficacy in advanced
NSCLC, and a tool to be considered in the design of future NSCLC
trials.
We are aware of the small cohort of patients in this study, which
limits the power of multivariate analyses and thus warrant
validation and refinement by larger scale prospective trials.
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